Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.66 |
| ▸ | FLT1 | P17948 | 6/20 | 0.66 |
| ▸ | FLT4 | P35916 | 4/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 12/20 | 0.64 |
| ▸ | RET | P07949 | 3/20 | 0.57 |
| ▸ | KIF5B | P33176 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564694 | 0.90 | EGFR (0.57) | KDRFGFR1FLT1FLT4FGFR2 | |
| SCHEMBL14564686 | 0.88 | FLT1 (0.75) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL5755914 | 0.88 | FLT1 (0.75) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL14564692 | 0.88 | KDR (0.61) | KDRFGFR1FLT1FLT4FGFR2 | |
| SCHEMBL14564693 | 0.87 | KDR (0.60) | KDRFGFR1FLT1FLT4FGFR2 | |
| SCHEMBL5465089 | 0.87 | FLT1 (0.73) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL5450340 | 0.87 | FLT1 (0.73) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL5958913 | 0.87 | KDR (0.76) | KDRFGFR1FLT1FLT4FGFR2 | |
| Hydrochloric Acid SCHEMBL5449012 | 0.86 | FLT1 (0.73) | KDRFGFR1FLT1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL5456504 | 0.86 | FLT1 (0.73) | KDRFGFR1FLT1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | KDR 93/4885FGFR1 712/4885FLT1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.